BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...

BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...

The study results reflect the effect of surgery with lymph node dissection alone in patients with high-grade invasive bladder cancer.

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...